Brodalumab in psoriasis: evidence to date and clinical potential
Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to mark...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2019-04-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://drugsincontext.com/brodalumab-in-psoriasis:-evidence-to-date-and-clinical-potential |